A prospective comparative study to evaluate the efficacy of nasal (GENEDIA W COVID-19 Ag (Ref. 643K)) and nasopharyngeal (GENEDIA W COVID-19 Ag (Ref. 643G)) antigenic rapid tests produced by Green Cross Medical Science Corp, Seoul, South Korea, for the identification of SARS-CoV-2 positive subjects has been performed by VisMederi Pharma. The study was performed as a collaboration with “Ospedale Universitario Sant’Andrea, Roma”. Results have shown the high sensibility and specificity of both rapid tests and were presented by Doctor Valeria Alfonsi at the 55° Siti (Società Italiana di Igiene) National Congress (Padova, September 28^th –October 1^st 2022).